Chancen und Grenzen der stereotaktisch fraktionierten Hochpräzisionsbestrahlung beim nichtkleinzelligen Lungenkarzinom im Stadium I/II
Tóm tắt
Từ khóa
Tài liệu tham khảo
Adebahr S, Collette S, Shash E et al (2015) LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective. Br J Radiol 88:20150036
AstraZeneca. A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515); clinicaltrials.gov; 2020 Mai [zitiert 31. 08. 2022]. Report No.: NCT03833154. Available online: https://clinicaltrials.gov/ct2/show/NCT03833154
Badra EV, Baumgartl M, Fabiano S et al (2021) Stereotactic radiotherapy for early stage non-small cell lung cancer: current standards and ongoing research. Transl Lung Cancer Res 10(4):1930–1949. https://doi.org/10.21037/tlcr-20-860
Bahig H, Filion E, Vu T et al (2016) Severe radiation pneumonitis after lung stereotactic ablative radiation therapy in patients with interstitial lung disease. Pract Radiat Oncol 6:367–374
Ball D, Mai GT, Vinod S et al (2019) Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. Lancet Oncol 20:494–503
Bezjak A, Paulus R, Gaspar LE et al (2019) Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non-small-cell lung cancer: NRG oncology/RTOG 0813 trial. J Clin Oncol 37:1316–1325
Cao C, Wang D, Chung C et al (2019) A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non-small cell lung cancer. J Thorac Cardiovasc Surg 157:362–373.e8
Chang JY (2017) Identifier NCT03110978—Stereotactic body radiation therapy with or without Nivolumab in treating patients with stage I–IIA or recurrent non-small cell lung cancer clinicaltrials.gov. https://clinicaltrials.gov/ct2/show/NCT03110978. Zugegriffen: 31. Aug. 2022
Chang JY, Senan S, Paul MA et al (2015) Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol 16(6):630–637
Chen Y, Guo W, Lu Y et al (2008) Dose-individualized stereotactic body radiotherapy for T1–3N0 non-small cell lung cancer: long-term results and efficacy of adjuvant chemotherapy. Radiother Oncol 88:351–358
De Ruysscher D, Faivre-Finn C, Moeller D et al (2017) European Organization for Research and Treatment of Cancer (EORTC) recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer. Radiother Oncol 124(1):1–10. https://doi.org/10.1016/j.radonc.2017.06.003
Foster CC, Rusthoven CG, Sher DJ et al (2019) Adjuvant chemotherapy following stereotactic body radiotherapy for early stage non-small-cell lung cancer is associated with lower overall: a National Cancer Database Analysis. Lung Cancer 130:162–168
Giuliani M, Mathew AS, Bahig H et al (2018) SUNSET: stereotactic radiation for Ultracentral non-small-cell lung cancer—a safety and efficacy trial. Clin Lung Cancer 19:e529–e532
Glick D, Lyen S, Kandel S et al (2018) Impact of pretreatment interstitial lung disease on radiation pneumonitis and survival in patients treated with lung stereotactic body radiation therapy (SBRT). Clin Lung Cancer 19:e219–e226
Grills IS, Hope AJ, Guckenberger M et al (2012) A collaborative analysis of stereotactic lung radiotherapy outcomes for early-stage non-small-cell lung cancer using daily online cone-beam computed tomography image-guided radiotherapy. J Thorac Oncol 7(9):1382–1393. https://doi.org/10.1097/JTO.0b013e318260e00d
Grills IS, Mangona VS, Welsh R et al (2010) Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. J Clin Oncol 28(6):928–935
Guckenberger M, Andratschke N, Alheit H et al (2014) Definition of stereotactic body radiotherapy: principles and practice for the treatment of stage I non-small cell lung cancer. Strahlenther Onkol 190(1):26–33. https://doi.org/10.1007/s00066-013-0450-y
Guckenberger M, Andratschke N, Dieckmann K et al (2017) ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer. Radiother Oncol 124:11–17
Guckenberger M, Wulf J, Mueller G et al (2009) Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation. Int J Radiat Oncol Biol Phys 74(1):47–54
Haasbeek CJ, Palma D, Visser O et al (2012) Early-stage lung cancer in elderly patients: a population-based study of changes in treatment patterns and survival in the Netherlands. Ann Oncol 23(10):2743–2747
Hallqvist A (2018) Identifier NCT03446547—Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736) (ASTEROID). ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03446547. Zugegriffen: 31. Aug. 2022
Haseltine JM, Rimner A, Gelblum DY et al (2016) Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree. Pract Radiat Oncol 6(2):e27–e33. https://doi.org/10.1016/j.prro.2015.09.012
Huang K, Senthi S, Palma DA et al (2013) High-risk CT features for detection of local recurrence after stereotactic ablative radiotherapy for lung cancer. Radiother Oncol 109:51–57
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer-ClinicalTrials.gov. [zitiert 31.8.2022]. Available online: https://clinicaltrials.gov/ct2/show/NCT02468024
Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF (2022) Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms Langversion 2.01, AWMF-Registernummer: 020/007OL. https://www.leitlinienpro-gramm-onkologie.de/leitlinien/lungenkarzinom/. Zugegriffen: 22.07.2022
Lindberg K, Grozman V, Karlsson K et al (2021) The HILUS-Trial—a prospective nordic multicenter phase 2 study of ultracentral lung tumors treated with stereotactic body radiotherapy. J Thorac Oncol. https://doi.org/10.1016/j.jtho.2021.03.019
LungTech: Stereotactic Body Radiotherapy (SBRT) of Inoperable Centrally Located NSCLC—Tabular View—ClinicalTrials.gov. [zitiert 31.08.2022]. Available online: https://clinicaltrials.gov/ct2/show/record/NCT01795521
National Cancer Institute (NCI) (2020) A randomized phase III trial of induction/consolidation atezolizumab (NSC #783608) + SBRT versus SBRT alone in high risk, early stage NSCLC. clinicaltrials.gov. https://clinicaltrials.gov/ct2/show/NCT04214262. Zugegriffen: 31. Aug. 2022 (Report No.: NCT04214262)
Nyman J, Hallqvist A, Lund JÅ et al (2016) SPACE—A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC. Radiother Oncol 121:1–8
Nestle U, Adebahr S, Kaier K et al (2020) Quality of life after pulmonary stereotactic fractionated radiotherapy (SBRT): Results of the phase II STRIPE trial. Radiother Oncol 148:82–88. https://doi.org/10.1016/j.radonc.2020.03.018
Radical Resection Vs. Ablative Stereotactic Radiotherapy in Patients With Operable Stage I NSCLC—Tabular View—ClinicalTrials.gov. [zitiert 31.8.2022]. Available online: https://clinicaltrials.gov/ct2/show/record/NCT01753414
Regnery S, Ristau J, Weykamp F et al (2022) Magnetic resonance guided adaptive stereotactic body radiotherapy for lung tumors in ultracentral location: the MAGELLAN trial (ARO 2021-3). Radiat Oncol 17(1):102. https://doi.org/10.1186/s13014-022-02070-x
Schanne DH, Nestle U, Allgauer M et al (2014) Stereotactic body radiotherapy for centrally located stage I NSCLC : a multicenter analysis. Strahlenther Onkol. https://doi.org/10.1007/s00066-014-0739-5
Takeda A, Kunieda E, Sanuki N et al (2012) Stereotactic body radiotherapy (SBRT) for solitary pulmonary nodules clinically diagnosed as lung cancer with no pathological confirmation: comparison with non-small-cell lung cancer. Cancer Treat Res 77:77–82
Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in OncologyVersion 3., 2022.J Natl Compr Canc Netw 20(5):497–530. https://doi.org/10.6004/jnccn.2022.0025;
Vansteenkiste J, De Ruysscher D, Eberhardt WE et al (2013) Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(Suppl 6):vi89–vi98
Verstegen NE, Oosterhuis JW, Palma DA et al (2013) Stage I–II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis. Ann Oncol 24(6):1543–1548
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy—Full Text View—ClinicalTrials.gov [zitiert 31.08.2022]. Available online: https://clinicaltrials.gov/ct2/show/NCT02984761
Videtic GMM, Donington J, Giuliani M et al (2017) Stereotactic body radiation therapy for early-stage non-small cell lung cancer: executive summary of an ASTRO evidence-based guideline. Pract Radiat Oncol 7:295–301
Wood DE (2015) National comprehensive cancer network (NCCN) clinical practice guidelines for lung cancer screening. Thorac Surg Clin 25:185–197